Baseline variables in the subgroup of patients with onset from 1996 treated with DMT
| Variable | Unweighted | sIPT-weighted | ||
| Men | Women | Men | Women | |
| N=3028 | N=6619 | N~3018 | N~6625 | |
| Mean age at onset (SD) | 34.3 (10.5) | 33.5 (10.2) | 33.8 (10.4) | 33.8 (10.3) |
| Mean age at entry (SD) | 37.7 (11.2) | 37.2 (10.8) | 37.4 (11.1) | 37.4 (10.8) |
| Mean disease duration at entry (SD) | 2.91 (3.74) | 3.17 (4.05) | 3.06 (3.86) | 3.09 (3.99) |
| Mean diagnostic delay, years (SD) | 2.49 (3.02) | 2.70 (3.32) | 2.62 (3.16) | 2.63 (3.24) |
| Mean EDSS score at entry (SD) | 2.19 (1.48) | 2.09 (1.41) | 2.18 (1.47) | 2.09 (1.41) |
| Mean relapses 24 months before entry (SD) | 1.63 (1.03) | 1.71 (1.09) | 1.68 (1.07) | 1.68 (1.06) |
| % with motor symptom at onset | 32.2 | 26.7 | 29.5 | 28.0 |
| Mean observation time (years) | ||||
| IQR | 8.52 (3.99–12.26) | 8.75 (4.17–12.48) | 8.67 (4.06–12.49) | 8.70 (4.12–12.38) |
| % of observation time with HE DMT* | 41.9 | 39.5 | 40.3 | 40.3 |
| Mean number of treatment switches per year of observation | 0.059 | 0.062 | 0.057 | 0.063 |
*HE DMT: high-efficacy DMT (natalizumab, fingolimod, ofatuzumab, alemtuzumab, cladribine, mitoxantrone, ocrelizumab, rituximab).
DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; sIPT, stabilised inverse probability treatment.